文献速递胸部MRCT

肺癌筛查中肺部MRI的成本效益

Cost-effectiveness of lung MRI in lung cancer screening.
PubMed 文献 · Eur Radiol · 2019-11-20

研究基于马尔可夫模型比较肺部MRI与低剂量CT在肺癌筛查中的性能与成本效益,纳入吸烟史36包年、从60岁开始的男女吸烟者;两者预期寿命无差异,MRI因假阳性筛查更少而成本效益更优,敏感性分析显示筛查成本低于396美元且特异度高于81%时MRI仍具成本效益。

要点

  • 马尔可夫模型显示,每年一次MRI筛查与低剂量CT筛查相比,男性和女性预期寿命均无差异。
  • MRI筛查使男性假阳性率从26%降至2.8%,女性从26%降至2.6%。
  • MRI相对低剂量CT的成本效益比为男性258,169美元、女性403,888美元。

核心结论

  • 在该肺癌筛查马尔可夫模型中,MRI具有与低剂量CT近乎等效的预期寿命获益,且相对低剂量CT具有更优的成本效益。

研究设计与样本

  • 研究类型为肺癌筛查的马尔可夫队列模型,纳入按性别、年龄和吸烟负荷设定肺癌发病率、进展和死亡率的模拟队列。
  • 模拟对象为男性和女性吸烟者(每天2包;吸烟史36包年),从60岁开始筛查。
  • 低剂量CT的敏感度和特异度取自MISCAN Lung Microsimulation,MRI的敏感度和特异度估计自德国肺癌筛查与干预试验已发表的亚研究。
  • 筛查、检查和治疗成本估计自已发表数据,并对MRI敏感度/特异度和成本进行了敏感性分析。

诊断标准与关键数值

  • MRI与低剂量CT筛查的预期寿命:男性13.28 vs. 13.29生命年;女性14.22 vs. 14.22生命年。
  • MRI相对低剂量CT的成本效益比为男性258,169美元、女性403,888美元。
  • 敏感性分析中,MRI在筛查成本低于396美元且特异度高于81%时仍具成本效益。
  • MRI筛查使假阳性研究从低剂量CT的男性26%降至2.8%、女性26%降至2.6%。

临床应用与阅片要点

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: Recent studies with lung MRI (MRI) have shown high sensitivity (Sn) and specificity (Sp) for lung nodule detection and characterization relative to low-dose CT (LDCT). Using this background data, we sought to compare the potential screening performance of MRI vs. LDCT using a Markov model of lung cancer screening.

METHODS: We created a Markov cohort model of lung cancer screening which incorporated lung cancer incidence, progression, and mortality based on gender, age, and smoking burden. Sensitivity (Sn) and Sp for LDCT were taken from the MISCAN Lung Microsimulation and Sn/Sp for MRI was estimated from a published substudy of the German Lung Cancer Screening and Intervention Trial. Screening, work-up, and treatment costs were estimated from published data. Screening with MRI and LDCT was simulated for a cohort of male and female smokers (2 packs per day; 36 pack/years of smoking history) starting at age 60. We calculated the screening performance and cost-effectiveness of MRI screening and performed a sensitivity analysis on MRI Sn/Sp and cost.

RESULTS: There was no difference in life expectancy between MRI and LDCT screening (males 13.28 vs. 13.29 life-years; females 14.22 vs. 14.22 life-years). MRI had a favorable cost-effectiveness ratio of $258,169 in men and $403,888 in women driven by fewer false-positive screens. On sensitivity analysis, MRI remained cost effective at screening costs < $396 dollars and Sp > 81%.

CONCLUSIONS: In this Markov model of lung cancer screening, MRI has a near-equivalent life expectancy benefit and has superior cost-effectiveness relative to LDCT.

KEY POINTS: • In this Markov model of lung cancer screening, there is no difference in mortality between yearly screening with MRI and low-dose CT. • Compared to low-dose CT, screening with MRI led to a reduction in false-positive studies from 26 to 2.8% in men and 26 to 2.6% in women. • Due to similar life-expectancy and reduced false-positive rate, we found a favorable cost-effectiveness ratio of $258,169 in men and $403,888 in women of MRI relative to low-dose CT.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Allen BD, Schiebler ML, Sommer G, et al. Cost-effectiveness of lung MRI in lung cancer screening. Eur Radiol. 2019. PMID: 31748855. doi:10.1007/s00330-019-06453-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。